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Abstract
There is high expectation for significant improvements in cancer patient care after completion of 
the human genome project in 2003. Through pains-taking analyses of genomic profiles in cancer 
patients, a number of targetable gene alterations have been discovered, with some leading to novel 
therapies, such as activating mutations of EGFR, BRAF and ALK gene fusions. As a result, 
clinical management of cancer through targeted therapy has finally become a reality for a subset of 
cancer, such as lung adenocarcinomas and melanomas. In this review, we will summarize how 
gene mutation discovery leads to new treatment strategies using non-small cell lung cancer 
(NSCLC) as an example. We will also discuss possible future implications of cancer genome 
analyses.
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1. INTRODUCTION
Targeted therapy is a special type of chemotherapy that targets the specific difference 
between cancer and normal cells. The concept of targeted therapy has been evolving over the 
years. In early years, targeted therapy means to selectively kill cancer cells based on a high 
cell proliferation rate of the cancer cells. In the last 10 years, significant progress in cancer 
treatments has been made through identification of novel genetic alterations in the cancer 
genome. Strategies in targeted therapy are largely based on gene mutation, pathway 
activation and alterations in the immune system. The most significant progress is the use of 
inhibitors for mutant kinases.
Discovery of BCR-ABL tyrosine kinase inhibitor STI571 (other names include imatinib 
mesylate and Gleevec) by Novartis scientists and successful clinical trials in CML patients 
by Drs. Druker and Sawyer (Druker et al., 2001a, 2001b) established a major milestone for 
targeted therapy, and promoted imatinib mesylate as the first-line drug for treatment of CML 
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with BCR-ABL gene fusion. Because imatinib mesylate also targets several other kinases, 
such as c-kit and PDGFRA, it has been shown to be effective for treatment of GI stromal 
tumor (GIST) (Demetri et al., 2002), NF1 (Robertson et al., 2012) as well as a subset of 
melanoma with c kit expression (Carvajal et al., 2011; Guo et al., 2011).
2. MAJOR GENETIC ALTERATIONS IN non-small cell lung cancer (NSCLC)
Lung cancer is the leading cause of cancer-related death, claiming ~158,000 American lives 
every year (which exceeds the combined mortality from breast, prostate and colorectal 
cancers) (Siegel et al., 2015). However, research in lung cancer is still under-funded, with 
$1442 per lung cancer death in comparison of $6849, $13419 and $26398 for colon, prostate 
and breast cancer respectively (Foundation, 2015). Currently, the 5-year survival rate for all 
types of lung cancer is ~17%. The majority of all newly diagnosed cases are patients with 
advanced lung cancer, which have a median survival of ~12 months following the first-line 
chemotherapy.
Common genetic alterations in lung cancer include p53 mutations/deletion, p16 gene 
silencing through methylation, LKB1 loss-of-function mutations and activating KRAS gene 
mutations. Overall, three major signaling pathways are affected in lung cancer: p53 
signaling, the RB/p16 signaling axis and the RAS signaling. Mutations or deletions of p53 
occur in 50% of NSCLC (Robles et al., 2002; Cooper et al., 2013). Although there are 
several strategies to target p53 signaling for cancer therapies, no drugs are now available for 
cancer treatment. P53 is regarded as the guardian of the genome, and p53 gene mutations 
result in many changes in the cancer genome (Lane, 1992; Khoo et al., 2014).
Inactivation in p16, via CpG island methylation, chromosomal deletion or point mutation, 
commonly occurs (~50%) in NSCLC although RB mutations are not common in NSCLCs 
(Otterson et al., 1994; Liggett and Sidransky, 1998; Sanchez-Cespedes et al., 1999). The p16 
protein inhibits phosphorylation of Rb through CDK4 (hence inhibitor of kinase 4, or INK4) 
(Liggett and Sidransky, 1998). It is known that p16 hypermethylation is associated with poor 
prognosis (Jin et al., 2001; Kim et al., 2001; Ng et al., 2002). In addition, Cyclin D1 is 
highly expressed in 47% of NSCLCs, which is also associated with a poor prognosis (Jin et 
al., 2001). Cyclin D1 inhibits RB function by enhancing RB phosphorylation by Cdk4. 
Furthermore, a second protein p14ARF that is encoded by the p16 locus, is transcribed from 
an alternate reading frame but results in a totally unrelated protein (Sanchez-Cespedes et al., 
1999). The p14ARF protein prevents MDM2-mediated p53 degradation, resulting in p53 
activation. The p14ARF gene inactivation is found in 19–37% of NSCLCs (Sanchez-
Cespedes et al., 1999; Sherr, 2001; Sherr and McCormick, 2002).
The RAS signaling pathway is frequently activated in lung cancer through mutations of 
several genes, including activated gene mutations in several growth factor receptors (see 
more below), KRAS and PIK3CA as well as loss-of-function gene mutations in PTEN and 
LKB1. While PTEN loss increases PIK3CA activity, LKB1 loss-of-function promotes 
mTOR signaling. Taken all together, almost all cancer cells have elevated RAS signaling 
(Cooper et al., 2013). Furthermore, in tumors with LKB1 inactivation, metabolism 
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inhibitors, such as phenformin, are predicted to be more effective in NSCLC treatment (Liu 
et al., 2013; Shackelford et al., 2013).
In the last few years, several targetable oncogenic mutations have been discovered in lung 
adenocarcinomas, including EGFR, HER2, FGFR1 and c-MET (reviewed in Thomas et al., 
2015). Additionally, several gene fusions involving ALK, RET, and ROS-1 have been 
reported. Other gene mutations include activating mutations in the PI3K/AKT pathway 
(PIK3CA and AKT) and the BRAF/MEK signaling (BRAF and MEK1/2).
EGFR gene mutation is often mutually exclusive from KRAS gene mutation. The same is 
true for ALK fusion and KRAS gene mutation, indicating that these are the driving 
mutations for NSCLC. While the specific inhibitors for KRAS are not clinically available, 
several specific small molecule inhibitors have been developed to target RAS downstream 
molecules, and have been approved for cancer treatment.
It is worth noting that the frequency of gene mutation varies among different patient 
population (Couraud et al. 2012). For example, EGFR gene mutation occurs only in 5% of 
American cancer patients who are current smokers, in 28% of never-smoking American 
patients, but ~50% of never-smoking Asian women. Similarly, ALK fusion occurs more 
frequently in never-smoking Asian women than in current smoking American men. The 
exact molecular mechanisms underlying the gene mutation for EGFR and ALK are still 
elusive. It is known that p53 gene mutations are often associated with smoking history, 
particularly G to T transversions. Furthermore, squamous cell carcinomas are different from 
adenocarcinomas in gene mutations. The frequency of p53 gene mutation is more common 
in squamous cell carcinomas (~90%) (vs. <50% in adenocarcinomas), while KRAS 
mutations occur in ~36% of lung adenocarcinomas but rarely in squamous cell carcinomas. 
Silencing of p16 is common in squamous cell carcinomas (~45%) but rare in 
adenocarcinomas. Mutations of EGFR, ALK, cMET and ROS-1 are rare in squamous cell 
carcinomas but commonly found in lung adenocarcinomas (8%–50% depending on smoking 
history, gene type and gender). Below we will focus on specific clinical drugs used to target 
specific gene alterations.
3. INHIBITORS FOR MUTANT KINASES
3.1 Mutant tyrosine kinase inhibitors
3.1.1 EGFR inhibitors—Identifying novel gene mutation has revolutionized treatment of 
NSCLC. The best example is EGFR. Initial studies using EGFR inhibitor gefitnib (Iressa) 
had tumor-inhibitory effects in only 10%–19% of patients with NSCLC (Fukuoka et al., 
2003). Later analyses indicate that most patients with activating EGFR mutations had better 
responses to gefitnib than those without such mutations (Lynch et al., 2004; Paez et al., 
2004). Initial observation indicates that treatment with the EGFR kinase inhibitor gefitinib 
causes tumor regression in some patients with NSCLC, more frequently in Asian population. 
EGFR activating gene mutations occur in 14% of lung adenocarcinomas. However, lung 
cancers from Asian women without smoking history have much higher percentage of EGFR 
gene mutations (~50%), twice of the rate in cancer patients from the US and Europe. 
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Following FDA approval of Gefitinib in 2003, a similar drug, Erlotinib (Tarceva ®) was also 
approved in 2004 (Fig. 1 for details).
Although EGFR inhibitors have been approved for treatment of NSCLC, most of the 
patients develop drug resistance within 15 months. In nearly 60% of treatment-resistant 
NSCLC, at least a secondary EGFR gene mutation is detectable. There are also other genetic 
changes, such as gene mutations in MET, BRAF, AXL, MAPK1 or PI3KCA. For example, 
T790 to M790 mutation (T790M) is the most common EGFR gene mutation, responsible for 
resistance to gefitinib treatment. Although it is difficult to role out possible acquired gene 
mutation in the EGFR gene, increasing evidence indicates pre-existence of EGFR mutation 
in a small number of cells of the original tumor and expansion of these cells with T790M 
EGFR during treatment (from 1 in 100,000 cells to 1 in 2 cells). Despite a lot of efforts in 
identifying an EGFR inhibitor that can block T790M EGFR functions, only recent studies 
identified AZD9291 as an irreversible inhibitor capable of inhibiting tumors with both 
T790M EGFR and other sensitive mutant EGFR (Finlay et al., 2014). Patients with T790M 
EGFR mutation treated with AZD9291 have ~13 months of progression-free survival (Janne 
et al., 2015), higher than the placebo group (~7 months) (Thress et al., 2015). Similarly, 
rociletinib is another well-tolerated drug that has a high response rate in T790M EGFR 
positive NSCLC tumors (Sequist et al., 2015). However, new resistance to these inhibitors 
eventually develops, and additional gene alterations are identified in the tumor (Piotrowska 
et al., 2015; Thress et al., 2015).
In addition, large scale screening of effective cell proliferation suppression leads to some 
novel findings. In patients-derived specimens, screening of effective inhibitors indicates that 
combined inhibition of EGFR and FGFR can suppress cell proliferation in EGFR mutant 
cell lines with a mutation in FGFR3 gene (Crystal et al., 2014). Hopefully, these studies will 
generate additional strategies to mitigate drug resistance to EGFR-based targeted therapy. 
During targeted therapy, in addition to genetic alterations, some NSCLC can transform into 
SCLC morphology, making metastasis more quickly.
3.1.2 ALK inhibitors—ALK caused by chromosome rearrangements is another important 
drug target in NSCLC (Fig. 1). About 8% of NSCLC contains ALK mutations, with ELM4-
ALK variant 1 as the most common alteration (Friboulet et al., 2014; Katayama et al., 2014; 
Shaw and Engelman, 2014). The most effective first-generation ALK inhibitor is crizotinib, 
but patients often relapse after treatment for 1–2 years. About one third of relapsed patients 
have additional ALK mutations whereas other patients have mutations in genes like EGFR 
and IGF1R, or bypass gene mutations downstream of ALK (such as MAP2K1 K57N and 
PIK3CA H1047R). Second- generation ALK inhibitors have shown effective activity against 
resistant ALK mutants, such as ceritinib, aletinib and PF-06463922. Currently, crizotinib is 
regarded as the first-line drug for ALK mutation-containing NSCLC, and ceritinib and 
alectinib are used for the second-line treatment of NSCLC (Gainor et al., 2015).
3.1.3. Additional tyrosine kinase inhibitors—Other mutant kinase genes in NSCLC 
include ROS-1 and RET (Fig. 1), and ALK inhibitor crizotinib has shown effectiveness 
through suppressing ROS-1 activity in NSCLC patients (Shaw et al., 2014). Because 
crizotinib is also effective in suppressing cMET, it is highly possible that crizotinib can be 
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used to treat NSCLC patients with cMET amplification. There are at least two multi-kinase 
inhibitors (vandetinib and cabozantinib) with RET tyrosine kinase inhibitor activity. Current 
clinical trials with these two drugs in the treatment of lung adenocarcinomas have shown 
some promising results (Gautschi et al., 2013; Mukhopadhyay et al., 2014).
Based on the experience in these tyrosine kinase inhibitors for lung cancer treatment, it has 
been recommended that it will be more effective to use the most potent tyrosine kinase 
inhibitor early in disease progression. Furthermore, it will beneficial to combine the targeted 
therapy with surgery and immunotherapy early on. Nevertheless, for all successful clinical 
trials or effective clinical care of cancer patients with NSCLC, identifying the genetic 
makeup of the tumor is the essential first step.
3.2 Serine/threonine kinase inhibitors
Many signal transducers are regulated by serine/threonine kinases, and thus inhibitors 
against serine/threonine kinases are known cancer drug targets for decades. However, only in 
the last 10 years, successful clinical trials using this type of inhibitors have been achieved. 
For example, B-RAF inhibitors can effectively shrink a subset of melanomas.
3.2.1 B-RAF inhibitors—BRAF mutations are common in melanomas, and successful 
clinical trials with Vemurafenib and Dabrafenib have led to FDA approval of these BRAF 
inhibitors for melanoma treatment in the clinic (Chapman et al., 2011; Poulikakos et al., 
2011). Only a small subset of NSCLC (2%) contains activating BRAF gene mutations (Kris 
et al., 2014). Due to the low incidence of BRAF mutations in NSCLC, most clinical trials 
using BRAF inhibitors were done together with other cancer types (Falchook et al., 2012) or 
as case reports (Rudin et al., 2013; Robinson et al., 2014; Schmid et al., 2015). In some 
studies, the response was short-lived, with relapse a few months later, and tumor recurrence 
was associated with other somatic gene mutations such as KRAS.
3.2.2. MEK inhibitors—As downstream signaling effectors, MEK1/2 have been important 
candidate targets for cancer therapy. A specific MEK1/2 inhibitor trametinib has been 
approved for treatment of melanomas with BRAF gene mutation after successful clinical 
trials (Flaherty et al., 2012a, 2012b). Because MEK1 mutation has been a major driver for 
resistance to BRAF or EGFR inhibitors, combination of BRAF inhibitor dabrafenib with 
trametinib has proven to be beneficial to the melanoma patients, with significant 
improvements in patient survival (Flaherty et al., 2012a, 2012b; Larkin et al., 2014; Long et 
al., 2014; Robert et al., 2015).
In NSCLC, MAPK2K1 (encoding MEK1) mutation is one of the driving factors responsible 
for drug resistance to EGFR inhibition (Ercan et al. 2012). Combination of EGFR inhibitor 
WZ4002 with MEK1/2 inhibitor trametinib prevents the appearance of EGFR resistance in 
EGFR mutant lung cancer in preclinical models (Tricker et al., 2015). Thus, it is anticipated 
that combined inhibition of EGFR and MEK1/2 will be more effective in NSCLC with 
EGFR mutations. Other studies also indicate more than additive effects with combination of 
two types of inhibitors (Heppt et al. 2015). Although PIK3CA and AKT gene mutations 
occur frequently in EGFR inhibitor resistant tumors, there are no FDA approved specific 
inhibitors to target PIK3CA and AKT.
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4. IMMUNOTHERAPIES OF NSCLC
One of the major features of cancer cells is to escape the immune surveillance system of the 
host by up-regulation of immune checkpoint proteins and immunosuppressive cytokines. As 
shown in Fig. 2, an increase in PD-L1/2 expression in the tumor cells and high expression of 
PD-1 in the T cells can trigger suppressive effects on T cell-mediated immune surveillance 
system, allowing the tumor cells to survive.
Recent clinical trials indicate that modulating immune checkpoint emerges as a promising 
strategy to overcome cancer cell-mediated immune suppression. In early 2012, specific 
neutralizing antibodies against PD-1 and PD-L1 already showed good activities in tumor 
shrinkage in NSCLC through targeting the PD-1/PD-L1/2 signaling axis. These antibodies-
based therapies are well tolerated. Although long-term survival is reported in treated 
patients, the response rate is generally low (around 20%) (Rizvi et al., 2015b). Patient 
selection is critical for immune therapy. Earlier studies showed that none of the PD-L1 
negative tumors respond to the treatment whereas 36% of PD-L1 positive tumors respond to 
the treatment (Topalian et al., 2012).
It is not known why only a subset of PD-L1 positive tumors responds to the treatment. 
Recent whole-exome sequencing of NSCLC treated with PD-L1 antibody pembrolizumab 
revealed that the genomic landscape of the tumor, not a single gene alteration, determines 
the response to PD-1 inhibition (Rizvi et al., 2015a). Other studies indicated that EGFR 
mutation can stimulate expression of PD-1 and PD-L1 in NSCLC (Akbay et al., 2013). The 
data from CTLA-4 neutralizing antibodies are impressive in melanomas (Weber et al., 2015) 
but more works remain to be done in NSCLC.
5. CURRENT CLINICAL PRACTICE GUIDELINES FOR NSCLC PATIENTS
5.1 Diagnosis
Based on the progress, both EU and the US medical oncology organizations have issued 
recommendation on new guidelines for clinical practice for NSCLC patients. In the 
guidelines, detection of EGFR mutations and ALK gene fusions is recommended for lung 
adenocarcinomas (Leighl et al., 2014; Reck et al., 2014) (Fig. 3). Mutation testing is 
recommended in all patients with advanced NSCLC as long as a component of 
adenocarcinoma is involved. Testing is not recommended in patients with a definite 
squamous cell carcinoma diagnosis. Testing is recommended for patients who are never/
former light smokers.
In contrast, routine use of serum markers such as carcinoembryonic antigen (CEA) is not 
recommended now. At present, contrast-enhanced computed tomography (CT) scan of the 
chest and upper abdomen is recommended for precise diagnosis of cancer. Disease stages 
should be determined during diagnosis to facilitate therapy strategies.
5.2 Treatment
Treatment options will vary depending on genetic alterations in the tumor (Fig. 3). For 
squamous cell carcinomas and EGFR/ALK negative adenocarcinomas, the first-line 
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treatment is platinum-based chemotherapy, and the second-line treatment for these tumors is 
docetaxel, and doctaxel plus ramucirumab (or nivolumab). For EGFR mutation positive 
adenocarcinomas, the first-line treatment is afatinib or erlotinib followed by chemotherapy 
(second line). For ALK translocation positive adenocarcinomas, the first-line treatment is 
crizotinib, and the second-line is certinib.
Because most targeted therapies will eventually end up with cancer relapse, subsequent lines 
of treatment options will be determined by the specific alterations in the cancer genome. For 
example, if EGFR T790M mutation occurs, newer generations of EGFR threonine kinase 
inhibitor (such as AZD9291) will be used. In comparison with the guideline 10 years ago, 
the new guidelines highlight the individual differences in different tumors, and the targeted 
therapy is aimed at a small proportion of the patient pool.
6. PERSPECTIVES
Targeted therapies in subsets of NSCLC have already extended the patient’s lifespan over 
one year (3.5 years for patients with targeted therapies vs. 2.4 years for patients without 
genotype-directed therapies) (Kris et al., 2014), highlighting significance of cancer genetic 
profiling and targeted therapy for clinical cancer care. Testing of EGFR mutations and ALK 
rearrangements is now recommended for all lung adenocarcinomas and lung cancer patients 
from never-smokers. However, NSCLC is still the number one cause of cancer-related death. 
Several major challenges are emerging in our efforts to reduce the mortality rate.
First of all, in the clinical setting, identifying the suitable patient population to perform 
targeted therapy or immune therapy at the earliest possible time point is critically important 
for a good outcome. A comprehensive care strategy (combined targeted therapies and 
immune therapy) is needed for all patients. With an increased number of rare genetic 
mutations in NSCLC (Cancer Genome Atlas Research, 2014) and increasing number of 
targeted drugs and immune therapy strategies, it will be feasible to perform genomic 
profiling or next-generation sequencing for each patient. It remains an issue as to cost 
coverage for these tests (afforded by medical insurance companies or out-of-pocket expense 
from the patients).
Second, it becomes clear that NSCLC consists of many small subsets of rare genotypes, and 
developing targeted therapies towards ever growing rare genotypes is a daunting task. Inter-
institutional collaborative efforts among clinicians and basic scientists, and more integration 
of tumor genotyping and clinical information are more needed than ever to make significant 
progress in the treatment of NSCLC.
Third, while the targeted therapy significantly improves the quality of life in the patients, 
most targeted therapies are short-lived (a few months to 2 years). This creates a major 
challenge in prolonging the lifespan of the cancer patients. Thus, it is critical to identify 
resistance mechanisms quickly in order to select additional strategies to militate against drug 
resistance.
In addition, despite all the clinical success in subsets of NSCLC patients, basic 
understanding of the mechanisms underlying tumor development in different genotypes has 
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lagged behind the clinical care of NSCLC. For example, it is still not clear why patients with 
EGFR mutations respond better to EGFR inhibitors than patients with EGFR 
overexpression. Similarly, it remains elusive why downstream signaling inhibitors (BRAF 
and MEK inhibitors) are not effective in patients with EGFR mutations or KRAS mutations. 
More funding for lung cancer-related basic research is urgently needed.
Looking forward, we anticipate much more progress in reducing NSCLC-related mortality 
in the next ten years through integration of technology with clinical care, through more 
collaboration among physicians and scientists, and through more research investment in lung 
cancer biology.
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Figure 1. Mutations of the genes in the growth factor/KRAS signaling axis in NSCLC
The frequency of gene mutations is shown in the bracket (mostly from the data of lung 
adenocarcinomas except for data of PI3K which is from the data from lung squamous cell 
carcinomas). Currently approved targeted drugs are shown in orange next to the target 
molecules. There are four drugs targeting EGFR and three drugs for ALK. ALK inhibitors 
are also active in suppressing ROS1 activity.
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Figure 2. The effect of anti-PD-1 on T cell function
In the absence of anti-PD-1 antibodies (nivolumab), oncogenic signaling induces expression 
of PD-L1 that can be recognized by PD-1 expressing T cells. PD-1 and PD-L1 interaction 
triggers signaling events leading to suppression of T cell activation and consequently 
immune tolerance of cancer cells. When PD-1 neutralizing antibodies nivolumaba are used, 
PD-1 and PD-L1 interaction is interrupted, allowing T cell activation to occur and resulting 
in immune detection of cancer cells and consequently elimination of cancer cells. PD-L1 
neutralizing antibodies have simiarl effects as PD-1 neutralizing antibodies. PD-L1, 
programmed death-ligand 1; PD-1, programmed death protein 1.
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Figure 3. A flow chart of the current standard care for NSCLC (particularly adenocarcinoma 
and squamous cell carcinoma)
This flow chart is the most recent guidelines for treatment of NSCLC patients. The treatment 
options depend o the genotype of the tumor. For example, tumors with EGFR gene 
mutations will be first treated with w specific EGFR inhibitor (highlighted in blue). IN 
contrast, tumors with ALK gene rearrangements will be treated with an ALK inhibitor 
(highlighted in red). For tumors without these somatic gene mutations, standard 
chemotherapy will be used (highlighted in black).
Although currently not approved yet, AZD9291 and rociletinib have shown effectiveness in 
EGFRT790M mutation positive adenocarcinomas, and may be approved soon. EGFR, 
epidermal growth factor receptor; ALK, anaplastic lymphoma receptor tyrosine kinase; 
NSCLC non-small cell lung cancer.
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